Updated Jul 16, 2026
Wein Matthew has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $2K.
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-10 | MGX | Metagenomi Therapeutics, Inc. | S — Open-market sale | 558 | $1.30 | $725 |
| 2026-04-03 | MGX | Metagenomi Therapeutics, Inc. | A — Grant or award | 11.0K | $0.00 | |
| 2026-03-09 | MGX | Metagenomi Therapeutics, Inc. | S — Open-market sale | 482 | $1.60 | $771 |
| 2025-12-08 | MGX | Metagenomi Therapeutics, Inc. | S — Open-market sale | 199 | $1.77 | $353 |
| 2025-12-01 | MGX | Metagenomi Therapeutics, Inc. | A — Grant or award | 96.0K | $1.60 | $154K |
| 2025-12-01 | MGX | Metagenomi Therapeutics, Inc. | S — Open-market sale | 199 | $1.81 | $360 |
Wein Matthew is a corporate insider — currently tracked as Insider of Metagenomi Therapeutics, Inc. (MGX). InsiderAlpha tracks every SEC Form 4 filing in real time.
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 4 open-market sales ($2K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Wein Matthew profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.